| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1049512864 |
| P356 | DOI | 10.1007/S00467-013-2716-0 |
| P932 | PMC publication ID | 4057986 |
| P698 | PubMed publication ID | 24337365 |
| P5875 | ResearchGate publication ID | 259321872 |
| P2093 | author name string | Shahid Nadeem | |
| Donald L Batisky | |||
| P2860 | cites work | The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents | Q22305963 |
| Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure | Q22306384 | ||
| Reducing cardiorenal risk through combination therapy with a direct renin inhibitor | Q26851307 | ||
| Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies | Q28036762 | ||
| Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients | Q28236175 | ||
| Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis | Q28280366 | ||
| Global burden of hypertension: analysis of worldwide data | Q28302545 | ||
| Direct renin inhibitors: the dawn of a new era, or just a variation on a theme? | Q28305525 | ||
| The biochemistry of the renin-angiotensin system and its role in hypertension | Q28321084 | ||
| Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials | Q31132556 | ||
| The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis | Q34122611 | ||
| Preventing microalbuminuria in type 2 diabetes | Q34552302 | ||
| The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition | Q34584353 | ||
| High blood pressure trends in children and adolescents in national surveys, 1963 to 2002. | Q34685572 | ||
| Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial | Q35031598 | ||
| Accuracy of blood pressure measurements reported in an electronic medical record during routine primary care visits | Q35536337 | ||
| Chronic renin inhibition with aliskiren improves glucose tolerance, insulin sensitivity, and skeletal muscle glucose transport activity in obese Zucker rats | Q35950287 | ||
| Renin inhibition with aliskiren: where are we now, and where are we going? | Q36409931 | ||
| Aliskiren, the first in a new class of direct renin inhibitors for hypertension: present and future perspectives | Q36979342 | ||
| Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria | Q37364926 | ||
| An issue of dependence: implications from the Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial | Q37394922 | ||
| ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial | Q37563491 | ||
| Aldosterone blockade in chronic kidney disease: can it improve outcome? | Q37772047 | ||
| Are we ready to use aliskiren in children? | Q37820390 | ||
| The renin-angiotensin-aldosterone system in 2011: role in hypertension and chronic kidney disease | Q37938867 | ||
| The changing face of pediatric hypertension in the era of the childhood obesity epidemic | Q38058726 | ||
| Essential hypertension predicted by tracking of elevated blood pressure from childhood to adulthood: the Bogalusa Heart Study | Q38891896 | ||
| Trends in blood pressure among children and adolescents | Q39281775 | ||
| Aliskiren prevents and ameliorates metabolic syndrome in fructose-fed rats. | Q40418079 | ||
| Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment | Q42627200 | ||
| The preparation, purification, and amino acid sequence of a polypeptide renin substrate | Q42822581 | ||
| Efficacy, safety and tolerability of aliskiren, a direct renin inhibitor, in women with hypertension: a pooled analysis of eight studies | Q43143679 | ||
| Strict blood-pressure control and progression of renal failure in children | Q43257210 | ||
| Additive antiproteinuric effect of ACE inhibitor and losartan in IgA nephropathy | Q43961791 | ||
| Blood pressure in children and target-organ damage later in life | Q44097905 | ||
| Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy | Q44378923 | ||
| Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren | Q44642058 | ||
| Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
| Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition | Q46842033 | ||
| Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators | Q48118604 | ||
| Measuring blood pressure for decision making and quality reporting: where and how many measures? | Q48846158 | ||
| Home blood pressure monitoring: take it to the bank. | Q50477807 | ||
| Aliskiren increased adverse events in patients with diabetes and kidney disease who were receiving ACE inhibitors or ARBs | Q57396198 | ||
| Manejo de la hipertensión arterial en niños y adolescentes: recomendaciones de la Sociedad Europea de Hipertensión | Q57605362 | ||
| Overweight, ethnicity, and the prevalence of hypertension in school-aged children | Q76393401 | ||
| Pharmacologic interruption of the renin-angiotensin system and the kidney: differential responses to angiotensin-converting enzyme and renin inhibition | Q77804729 | ||
| Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta | Q77894894 | ||
| Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus | Q79267114 | ||
| Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment | Q79631774 | ||
| Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats | Q81166769 | ||
| Not ready for prime time: aliskiren for treatment of hypertension or proteinuria in children | Q82905378 | ||
| Pediatric ambulatory blood pressure monitoring: diagnosis of hypertension | Q86605460 | ||
| Pharmacokinetics, safety profile, and efficacy of aliskiren in pediatric patients with hypertension | Q86642394 | ||
| Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution? | Q94519175 | ||
| P433 | issue | 11 | |
| P304 | page(s) | 2105-2111 | |
| P577 | publication date | 2013-12-14 | |
| P1433 | published in | Pediatric Nephrology | Q15749796 |
| P1476 | title | Aliskiren, the first direct renin inhibitor: assessing a role in pediatric hypertension and kidney diseases | |
| P478 | volume | 29 |
Search more.